Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.46 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | CLPP | Q16740 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917345 | 0.86 | SMN1; SMN2 (0.47) | CHRM3CHRM4 | |
| SCHEMBL4921326 | 0.85 | UBE2M (0.49) | CHRM3CHRM4MEN1KMT2AUBE2M | |
| SCHEMBL4924768 | 0.84 | ACKR3 (0.50) | CHRM3CXCR3MEN1KMT2AUBE2M | |
| SCHEMBL4923919 | 0.83 | CHRM3 (0.48) | CHRM3CXCR3MEN1KMT2AUBE2M | |
| SCHEMBL4923478 | 0.80 | ALDH1A1 (0.55) | KCNH2 | |
| SCHEMBL4924858 | 0.79 | CHRM3 (0.54) | CHRM3CXCR3CHRM4PRKAA2MEN1 | |
| SCHEMBL4924876 | 0.79 | SMN1; SMN2 (0.46) | CHRM3CHRM4 | |
| SCHEMBL4922782 | 0.79 | TSHR (0.55) | CHRM4KCNH2 | |
| SCHEMBL4921834 | 0.79 | UBE2M (0.48) | CHRM3CHRM4MEN1KMT2AUBE2M | |
| SCHEMBL4922742 | 0.78 | TSHR (0.52) | CHRM3CXCR3CHRM4PRKAA2USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | CHRM3 37/4885CXCR3 13/4885CHRM4 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.